The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).
Fabrice Andre
No relevant relationships to disclose
Thomas Denis Bachelot
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis; Roche
Research Funding - Novartis; Roche
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; Roche; SERVIER
Research Funding - Novartis
Monica Arnedos
No relevant relationships to disclose
Veronique Dieras
No relevant relationships to disclose
Magali Lacroix-Triki
No relevant relationships to disclose
Vladimir Lazar
No relevant relationships to disclose
David Gentien
No relevant relationships to disclose
Pascale Cohen
No relevant relationships to disclose
Anthony Goncalves
No relevant relationships to disclose
Ludovic Lacroix
No relevant relationships to disclose
Max Chaffanet
No relevant relationships to disclose
Florence Dalenc
No relevant relationships to disclose
Marie-Christine Mathieu
No relevant relationships to disclose
Ivan Bieche
No relevant relationships to disclose
Sylviane Olschwang
No relevant relationships to disclose
Qing Wang
No relevant relationships to disclose
Frederic Commo
No relevant relationships to disclose
Marta Jimenez
No relevant relationships to disclose
Herve R. Bonnefoi
No relevant relationships to disclose